Skip to main content

Clinical Trials | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

EA9213: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with relapsed or refractory T Cell ALL. This phase II trial studies how well daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy. Additional information can be found here: https://clinicaltrials.gov/study/NCT05289687?term=EA9213&rank=1 (ClinicalTrials.gov Identifier: NCT05289687)